The FDA Has Awarded Regenerative Medicine Advanced Therapy Designation to an Experimental Drug for X-Linked Myotubular Myopathy
The investigational drug AT132 has been awarded Regenerative Medicine Advanced Therapy designation for the treatment of X-linked Myotubular Myopathy by the United States FDA. You can read the source press…